News coverage about TherapeuticsMD (NASDAQ:TXMD) has been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TherapeuticsMD earned a news impact score of 0.19 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.749739582075 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Financial Review: Salix Pharmaceuticals (SLXP) vs. TherapeuticsMD (TXMD) (americanbankingnews.com)
- Financial Comparison: TherapeuticsMD (TXMD) & Its Rivals (americanbankingnews.com)
- Head-To-Head Survey: TherapeuticsMD (TXMD) versus Its Peers (americanbankingnews.com)
- Financial Survey: TherapeuticsMD (TXMD) and Its Peers (americanbankingnews.com)
- TherapeuticsMD, Inc. (TXMD) Given Average Rating of “Buy” by Analysts (americanbankingnews.com)
TherapeuticsMD (NASDAQ:TXMD) traded down $0.09 during mid-day trading on Friday, reaching $5.81. 1,910,000 shares of the company were exchanged, compared to its average volume of 3,870,000. TherapeuticsMD has a 52-week low of $3.50 and a 52-week high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Monday, November 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.03. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The company had revenue of $4.42 million for the quarter, compared to the consensus estimate of $5.36 million. During the same quarter in the prior year, the firm earned ($0.13) earnings per share. The company’s revenue for the quarter was down 19.7% compared to the same quarter last year. analysts forecast that TherapeuticsMD will post -0.38 EPS for the current year.
A number of research analysts have commented on the stock. Oppenheimer Holdings, Inc. set a $10.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a research note on Thursday, August 17th. Deutsche Bank AG assumed coverage on shares of TherapeuticsMD in a research note on Friday, July 21st. They issued a “buy” rating and a $10.00 price objective on the stock. Morgan Stanley assumed coverage on shares of TherapeuticsMD in a research note on Friday, September 8th. They issued an “equal weight” rating and a $6.00 price objective on the stock. Stifel Nicolaus restated a “buy” rating and issued a $20.00 price objective on shares of TherapeuticsMD in a research note on Monday, August 21st. Finally, Zacks Investment Research upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Thursday, August 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $14.72.
WARNING: “TherapeuticsMD (TXMD) Earning Somewhat Favorable Media Coverage, Report Finds” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://ledgergazette.com/2017/11/17/therapeuticsmd-txmd-earning-somewhat-favorable-media-coverage-report-finds.html.
In other TherapeuticsMD news, Director Tommy G. Thompson purchased 5,000 shares of TherapeuticsMD stock in a transaction on Wednesday, August 30th. The shares were bought at an average price of $5.99 per share, with a total value of $29,950.00. Following the completion of the acquisition, the director now directly owns 3,555 shares of the company’s stock, valued at $21,294.45. The transaction was disclosed in a document filed with the SEC, which is available through this link. 23.92% of the stock is owned by corporate insiders.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.